bullish
Pharmaessentia Corp (6446 TT): Key Drug Is Advancing Commercialization Globally
Tina has highlighted this Insight as a Top Pick
3.5k Views05 May 2022 18:12
SUMMARY
- Pharmaessentia Corp (6446 TT) is advancing global commercialization of its flagship drug, Besremi, the first FDA-approved medication for polycythemia vera that patients can take regardless of their treatment history.
- Thus far, Besremi has been commercialized for polycythemia vera in 23 countries. Launch preparation is underway in four geographies including Japan, China, Singapore, and Hong Kong.
- The company is conducting clinical trials for Besremi for other indications, including COVID-19. Pharmaessentia also has a rich pipeline of clinical-stage drug candidates.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Besremi Starts 2023 on Strong Note; Geography Expansion Continues15 Feb 2023
- Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US14 Nov 2022
- Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down10 Aug 2022
- Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow25 Nov 2021
x